Home Platform Pipeline Tools About Investors Contact Get in touch →
Research tools and services

iPSC-derived cells
for drug discovery.

Research-grade and GMP-compatible iPSC-derived cells from the matched bank, with the disease models, custom services, and characterization reports researchers need.

01 / 02
Product catalog
Research and GMP.
We supply research-grade and GMP-compatible iPSC-derived cells, disease models, and custom services for non-animal testing, drug screening, and therapeutic development.
iPSC lines
HLA-characterized, QC-tested iPSC lines from our 65 super donor panel. Each line ships with a complete certificate of analysis covering pluripotency, karyotype, identity, and sterility.
Mesenchymal stem cells
iPSC-derived mesenchymal stem cells with a doubling time of about twenty hours. Manufactured under xeno-free conditions, GMP-compatible.
iPSC-derived cardiomyocytes
iPSC-derived cardiomyocytes for cardiac drug screening, disease modeling, and safety pharmacology. Especially well suited to hERG and QT prolongation studies.
Custom differentiation
Custom iPSC differentiation to client specification. Disease-specific or patient-derived lines delivered with full characterization reports.
02 / 02
Services
For drug discovery teams.
Two areas where we work directly with pharma and biotech research teams.
Drug screening studies
Cardiac safety screening using iPSC-derived cardiomyocytes, including hERG, QT prolongation, and arrhythmia assays. Disease modeling against more than one hundred conditions using the 85,000-sample biobank, which includes more than 4,900 disease-patient samples.
Custom cell line development
Patient-derived iPSC lines for disease modeling. Each line ships with a full characterization report covering pluripotency markers, karyotype, and differentiation validation, plus a certificate of analysis.
[ Request a quote ]

Tell us what you need
and we will price it.

Most quotes turn around in two business days. We work with academic groups, biotech teams, and large pharma research programs.

Request a quote → See the platform →